UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

British journal of cancer, 2014-11, Vol.111 (10), p.1909-1916

2014

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

British journal of cancer, 2010-04, Vol.102 (9), p.1371-1377

2010

Link zum Volltext

Verfügbarkeit prüfen

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

British journal of cancer, 2017-08, Vol.117 (4), p.478-484

2017

Link zum Volltext

Verfügbarkeit prüfen

Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms

Annals of oncology, 2013-11, Vol.24 (11), p.2927-2928

2013

Link zum Volltext

Verfügbarkeit prüfen

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer

Annals of oncology, 2012-09, Vol.23 (9), p.2470-2471

2012

Link zum Volltext

Verfügbarkeit prüfen

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

British journal of cancer, 2015-03, Vol.112 (7), p.1190-1198

2015

Link zum Volltext

Verfügbarkeit prüfen

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

British journal of cancer, 2012-08, Vol.107 (4), p.639-645

2012

Link zum Volltext

Verfügbarkeit prüfen

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report

Pharmaceutical research, 2005-04, Vol.22 (4), p.499-511

2005

Link zum Volltext

Verfügbarkeit prüfen

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

British journal of cancer, 2014-12, Vol.111 (12), p.2383-2383

2014

Link zum Volltext

Verfügbarkeit prüfen

9400 ORAL Prognostic and Predictive Factors in Advanced Soft Tissue Sarcoma Patients Treated in an EORTC STBSG Global Network Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo (EORTC 62072, PALETTE)

European journal of cancer (1990), 2011, Vol.47, p.S662-S662

2011

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

The New England journal of medicine, 2013-08, Vol.369 (8), p.722-731

2013

Link zum Volltext

Verfügbarkeit prüfen

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

Blood, 2005-12, Vol.106 (13), p.4389-4396

2005

Link zum Volltext

Verfügbarkeit prüfen

Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A02+ patients with synovial sarcoma (NCT01343043)

Annals of oncology, 2016-10, Vol.27, p.vi368-vi368

2016

Link zum Volltext

Verfügbarkeit prüfen

1114 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

European journal of cancer supplements, 2009, Vol.7 (2), p.119-119

2009

Link zum Volltext

Verfügbarkeit prüfen

Erratum: Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

British journal of cancer, 2014-12, Vol.111 (12), p.2383-2383

2014

Link zum Volltext

Verfügbarkeit prüfen

An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e15128-e15128

2010

Link zum Volltext

Verfügbarkeit prüfen

1093 Low or undetectable levels of MPL (thrombopoietin receptor gene) mRNA expression on tumour cell lines and primary tumours compared with EPOR, ERBB2, and IGF1R

European journal of cancer supplements, 2009, Vol.7 (2), p.112-113

2009

Link zum Volltext

Verfügbarkeit prüfen

Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4633-4633

2011

Link zum Volltext

Verfügbarkeit prüfen

Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.345-345

2011

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

Clinical cancer research, 2004-07, Vol.10 (13), p.4363-4368

2004

Link zum Volltext

Verfügbarkeit prüfen

Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated patients (pts) with renal cell carcinoma (RCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3061-3061

2011

Link zum Volltext

Verfügbarkeit prüfen

Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4553-4553

2011

Link zum Volltext

Verfügbarkeit prüfen

Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3048-3048

2010

Link zum Volltext

Verfügbarkeit prüfen

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 1998-06, Vol.21 (12), p.1177-1181

1998

Link zum Volltext

Verfügbarkeit prüfen

Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.303-303

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(89)

Sprache

Englisch
(89)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(27)
Female
(20)
Male
(19)
Oncology
(19)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Adult
(17)
Middle Aged
(17)
Aged
(12)
Pyrimidines - Therapeutic Use
(12)
Sulfonamides - Therapeutic Use
(12)
Carcinoma, Renal Cell - Drug Therapy
(10)
Kidney Neoplasms - Drug Therapy
(10)
Tumors
(10)
Antineoplastic Agents - Therapeutic Use
(9)
Treatment Outcome
(9)
Hematology
(7)
Prognosis
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

9400 ORAL Prognostic and Predictive Factors in Advanced Soft Tissue Sarcoma Patients Treated in an EORTC STBSG Global Network Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo (EORTC 62072, PALETTE)

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A02+ patients with synovial sarcoma (NCT01343043)

1114 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

Erratum: Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC)

1093 Low or undetectable levels of MPL (thrombopoietin receptor gene) mRNA expression on tumour cell lines and primary tumours compared with EPOR, ERBB2, and IGF1R

Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials

Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma

A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated patients (pts) with renal cell carcinoma (RCC)

Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC)

Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC)

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma

Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma

Suchergebnisse filtern